Lupin launches generic GERD drug in the US market

NEW DELHI: Drug major Lupin today said it has launched a generic version of Japan-headquartered Eisai Inc's Aciphex delayed-release tablets, used to treat gastroesophageal reflux disease, in the US market.

The company's US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market after having received approval to market it from the US Food and Drug Administration, according to a statement by Lupin.

Lupin's product is generic equivalent of Eisai Inc's Aciphex delayed-release tablets, 20mg, and is indicated for the treatment of gastroesophageal reflux disease (GERD), it added.

According to IMS MAT Jun 2013 sales data, Aciphex delayed-release tablets, 20mg, had annual US sales of around $864.3 million.

Shares of Lupin were trading at Rs 886.30 a piece on the BSE in late afternoon trade, up 0.30 per cent from its previous close.